Titan Medical (Nasdaq:TMDI) announced today that executive Perry Genova will depart the company effective immediately.
Genova, who served as senior VP of research and product development, will leave Titan following what the single access robotic-assisted surgery technology developer described as careful consideration and a review of the company’s future needs.
“As we transform from a technology research and development company to a company focused on regulatory clearance and commercialization, our needs continue to evolve,” Titan interim President, CEO and Chair Paul Cataford said in a news release. “We wish Perry success in his future endeavors.“
Titan Medical develops the Enos robotic single-access surgical system with an ergonomic focus. The company aims to provide a surgical experience that imitates a surgeon’s real-life movements, with multi-articulating instruments, dexterity and the ability to exert the forces necessary to complete everyday surgical tasks. Titan initially plans to pursue gynecologic surgical indications for Enos.
